evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,678 questions · 4,859 findings · 283 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,225 · 25.2%GRADE not reported 215 · 4.4%Very low 1,241 · 25.5%Low 1,210 · 24.9%Moderate 776 · 16%High 192 · 4%

Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis vs on‐demand therapy

Proportion with zero bleeds · people without inhibitors

Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis showed no clear difference in proportion of participants with zero bleeds compared with on‐demand therapy (low certainty).

1 finding from 1 review

Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis vs on‐demand therapy

All adverse events · people without inhibitors

Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis vs on‐demand therapy

Serious adverse events · people without inhibitors

Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Extracorporeal membrane oxygenation (ECMO) vs usual care

All‐cause mortality: all ECMO studies · severe cardiorespiratory failure and cardiac arrest

Summary of findings table ‐ Extracorporeal membrane oxygenation (ECMO) probably leads to lower all‐cause mortality: all ECMO studies compared with conventional care (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Extracorporeal membrane oxygenation (ECMO) vs usual care

All‐cause mortality: VV ECMO subgroup · severe cardiorespiratory failure and cardiac arrest

Summary of findings table ‐ Extracorporeal membrane oxygenation (ECMO) probably leads to lower all‐cause mortality: VV ECMO subgroup compared with conventional care (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Extracorporeal membrane oxygenation (ECMO) vs usual care

All‐cause mortality: VA ECMO subgroup · severe cardiorespiratory failure and cardiac arrest

Summary of findings table ‐ Extracorporeal membrane oxygenation (ECMO) showed no clear difference in all‐cause mortality: VA ECMO subgroup compared with conventional care (low certainty).

1 finding from 1 review

Summary of findings table ‐ Extracorporeal membrane oxygenation (ECMO) vs usual care

All‐cause mortality at 6 months (subgroup) · severe cardiorespiratory failure and cardiac arrest

Summary of findings table ‐ Extracorporeal membrane oxygenation (ECMO) showed no clear difference in all‐cause mortality: ECPR subgroup compared with conventional care (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Extracorporeal membrane oxygenation (ECMO) vs usual care

Major hemorrhage · severe cardiorespiratory failure and cardiac arrest

Summary of findings table ‐ Extracorporeal membrane oxygenation (ECMO) probably leads to higher major hemorrhage: all available studies compared with conventional care (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Extracorporeal membrane oxygenation (ECMO) vs usual care

Neurologic injury: all available studies · severe cardiorespiratory failure and cardiac arrest

Summary of findings table ‐ Extracorporeal membrane oxygenation (ECMO) showed no clear difference in neurologic injury: all available studies compared with conventional care (moderate certainty).

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Survival · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype
1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Quality of life: total score · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

The review found no eligible studies for this question.

1 finding from 1 review